Oncotarget is a free access journal that posts articles on oncology and other related medical fields. Impact Journals published the first Oncotarget journal in 2010. Mikhail Blagosklonny and Andrei Gudkov are the editors-in-chief of the journal. The journal, indexed by PubMed, MEDLINE, and Scopus, is peer-reviewed hence is trustworthy and publishes meaningful content. Oncotarget has had a significant impact in the medical field particularly in the fight against cancer. The journal also covers other disciplines including Cell Biology, Immunology, Cardiology and Neuroscience among others.Scimago Journal and Country Rank give Oncotarget an H Index of 66 and a score of 1.927 to place it among the top five free access oncology journals. This shows how much people love the journal with over six thousand works in 2016 and nearly three hundred thousand references. Oncotarget is the most cited open-access journal with more than twenty-two thousand cites.
IntegraGen, a firm majoring in development of genotypic information and diagnostic tools for oncology, recently published findings of a medical trial they carried out on Oncotarget. The study aims at finding reprieve for patients with metastatic colorectal cancer in both men and women. It is the second most common type of cancer in men and third most common in men. There are more than a million reports of new cases yearly and nearly seven hundred deaths as a result of this type of cancer worldwide each year. One in every four colorectal cancer patients has a metastatic disease at the time of diagnosis with half of these patients developing metastatic colorectal cancer afterward. This type of cancer is responsible for 8.5% of all cancer deaths.IntegraGen launched the study to predict survival chances and possible patient response to anti-EGFR therapy. They analyzed miR-31-3p expression in tumor samples from patients.
This is the first positive theranostic test available for patients. The study confirmed the correlation between miR-31-3p expression and cetuximab usefulness in those with the metastatic colorectal type of cancer. The analysis predicts potential benefits a patient may get when under first-line anti-EGFR therapy as opposed to anti-VEGF treatment. IntegraGen recently launched a ready-to-use kit that quantifies the expression of the miR-31-3p in FFPE tumor samples. Patients do not have to depend solely on chemotherapy as the solution to patients with metastatic colorectal cancer. According to Prof. John Bridgewater, a co-author of the study believes this is another way of identifying patients who will benefit from the new anti-EGFR therapy. The study, therefore, could prove very helpful to metastatic cancer patients as it surely is a better treatment approach. IntegraGen recently reached an agreement with CERBA laboratories to license the development of a lab-developed test that adequately measures the expression of the miR-31-3p in patients with metastatic colorectal cancer.The publication is peer-reviewed thus it provides a meaningful addition to the growing field of research on the need to measure miR-31-3p in tumors from metastatic colorectal cancer patients. With this study and the findings, Yann Gaston-Mathe of IntegraGen believes benefits of precision medicine will soon be realized by many.